These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19885570)

  • 1. The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells.
    Ling LU; Lin H; Tan KB; Chiu GN
    Int J Oncol; 2009 Dec; 35(6):1463-71. PubMed ID: 19885570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells.
    Schwartz GK; Haimovitz-Friedman A; Dhupar SK; Ehleiter D; Maslak P; Lai L; Loganzo F; Kelsen DP; Fuks Z; Albino AP
    J Natl Cancer Inst; 1995 Sep; 87(18):1394-9. PubMed ID: 7658500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C.
    Sachs CW; Safa AR; Harrison SD; Fine RL
    J Biol Chem; 1995 Nov; 270(44):26639-48. PubMed ID: 7592889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
    Mans DR; Grivicich I; Peters GJ; Schwartsmann G
    Eur J Cancer; 1999 Dec; 35(13):1851-61. PubMed ID: 10674003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between CoFactor and Leucovorin activity applied in combination with 5-fluorouracil against two human colon cancer cell lines.
    Bjelogrlić SK; Srdić T; Radulović S
    J BUON; 2007; 12(1):71-6. PubMed ID: 17436405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
    Harris SM; Mistry P; Freathy C; Brown JL; Charlton PA
    Br J Cancer; 2005 Feb; 92(4):722-8. PubMed ID: 15700035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway.
    Coward J; Ambrosini G; Musi E; Truman JP; Haimovitz-Friedman A; Allegood JC; Wang E; Merrill AH; Schwartz GK
    Autophagy; 2009 Feb; 5(2):184-93. PubMed ID: 19098447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
    Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
    Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
    Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
    Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.
    Guichard S; Cussac D; Hennebelle I; Bugat R; Canal P
    Int J Cancer; 1997 Nov; 73(5):729-34. PubMed ID: 9398054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.
    Aschele C; Baldo C; Sobrero AF; Debernardis D; Bornmann WG; Bertino JR
    Clin Cancer Res; 1998 May; 4(5):1323-30. PubMed ID: 9607593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
    Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D
    Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion.
    Pham MH; Delestre L; Dewitte A; Wattez N; Lepretre F; Lansiaux A
    Anticancer Res; 2015 Nov; 35(11):5983-91. PubMed ID: 26504021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
    Yang D; Qu J; Qu X; Cao Y; Xu L; Hou K; Feng W; Liu Y
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):575-86. PubMed ID: 26208739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of endonuclease G-mediated apopotosis in human oral squamous cell carcinoma cells by protein kinase C inhibitor safingol.
    Hamada M; Sumi T; Iwai S; Nakazawa M; Yura Y
    Apoptosis; 2006 Jan; 11(1):47-56. PubMed ID: 16374540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
    Zhu H; Zhao F; Yu S; He J; Deng L; Yi C; Huang Y
    Int J Mol Med; 2012 Nov; 30(5):1087-94. PubMed ID: 22922573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy.
    Hofmann C; Buttenschoen K; Straeter J; Henne-Bruns D; Kornmann M
    Anticancer Res; 2005; 25(2A):795-804. PubMed ID: 15868911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.